162 related articles for article (PubMed ID: 36210027)
61. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis.
Ali N; Butt A; Altaf B; Adil SN; Shaikh MU
Transplant Proc; 2021; 53(1):386-390. PubMed ID: 32773285
[TBL] [Abstract][Full Text] [Related]
62. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
63. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
[TBL] [Abstract][Full Text] [Related]
64. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
65. Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.
Man Y; Lu Z; Yao X; Gong Y; Yang T; Wang Y
Front Immunol; 2022; 13():911174. PubMed ID: 35720412
[TBL] [Abstract][Full Text] [Related]
66. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
67. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
68. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
[TBL] [Abstract][Full Text] [Related]
69. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
[TBL] [Abstract][Full Text] [Related]
70. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
71. Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor.
Stockschläder M; Löliger C; Krüger W; Zeller W; Heyll A; Schönrock-Nabulsi P; Zander A
Bone Marrow Transplant; 1995 Nov; 16(5):719-22. PubMed ID: 8547873
[TBL] [Abstract][Full Text] [Related]
72. Early engraftment of G-CSF-primed allogeneic bone marrow transplantation in pediatric patients regardless of donor-recipient weight differences.
Kim H; Kang HJ; Lee JW; Park KD; Shin HY; Ahn HS
Ann Hematol; 2012 May; 91(5):751-758. PubMed ID: 22076065
[TBL] [Abstract][Full Text] [Related]
73. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
74. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
[TBL] [Abstract][Full Text] [Related]
75. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
76. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study.
Frangoul H; Nemecek ER; Billheimer D; Pulsipher MA; Khan S; Woolfrey A; Manes B; Cole C; Walters MC; Ayas M; Ravindranath Y; Levine JE; Grupp SA
Blood; 2007 Dec; 110(13):4584-7. PubMed ID: 17827386
[TBL] [Abstract][Full Text] [Related]
77. Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients.
Chen Y; Xu LP; Liu KY; Chen H; Chen YH; Zhang XH; Wang Y; Wang FR; Han W; Wang JZ; Yan CH; Huang XJ
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27888540
[TBL] [Abstract][Full Text] [Related]
78. Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia--a single-center experience.
Wang H; Wang Z; Zheng X; Ding L; Zhu L; Yan H; Guo Z
Cytotherapy; 2013 Sep; 15(9):1118-25. PubMed ID: 23806238
[TBL] [Abstract][Full Text] [Related]
79. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
[TBL] [Abstract][Full Text] [Related]
80. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]